GSK’s triple drug cuts flare-ups in chronic lung disease

LONDON (Reuters) – An experimental three-in-one inhaled drug from GlaxoSmithKline significantly cut flare-ups in patients with chronic lung disease in a clinical trial, researchers said on Tuesday.

LONDON (Reuters) – An experimental three-in-one inhaled drug from GlaxoSmithKline significantly cut flare-ups in patients with chronic lung disease in a clinical trial, researchers said on Tuesday.
Original Article

more recommended stories